Inside Peptides
Search
Menu

Cardiovascular Peptides & Hemodynamic Regulation

Cardiovascular peptide research examines the peptide hormones that govern arterial blood pressure, vascular endothelial tone, myocardial remodeling, and renal fluid balance. Encompasses natriuretic peptides (ANP, BNP), the renin-angiotensin-aldosterone system, and vasopressin in critical care shock.

Diagram of cardiac myocytes releasing natriuretic peptides (ANP/BNP) to signal renal glomeruli and vascular smooth muscle
Cardiac natriuretic peptides bind guanylyl cyclase receptors to promote vasodilation and renal sodium excretion.

Field Summary & Status

Strong Evidence
Field Maturity Clinically Validated / High
Primary Receptors NPR-A / NPR-B, V1a / V2, AT1 / AT2, Neprilysin
Target Tissues Vascular Endothelium, Vascular Smooth Muscle, Renal Tubules, Cardiac Myocytes
Key Approved Medicines Angiotensin II (Giapreza), Vasopressin (Vasostrict), Sacubitril/Valsartan (Entresto ARNI), Nesiritide
Lead Investigational Classes Designer Natriuretic Peptides (Cenderitide), Relaxin analogues (Serelaxin)
Last Updated 2026-10-06

Hemodynamic Tone & Neurohumoral Regulation

Cardiovascular physiology is governed by opposing neurohumoral peptide networks that maintain arterial blood pressure and intravascular volume. The vasoconstrictive arm is driven by the Renin-Angiotensin-Aldosterone System (RAAS) and arginine vasopressin, which promote arteriolar constriction and renal water retention.

Counterbalancing these hypertensive signals is the cardiac natriuretic peptide system, comprising Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP). Released by atrial and ventricular myocytes in response to wall stretch and volume overload, natriuretic peptides bind particulate guanylyl cyclase receptors to trigger vasodilation, natriuresis, and diuresis.

Clinical pharmacology in this field has evolved from acute recombinant peptide infusions to dual neprilysin inhibition (sacubitril), which prevents the enzymatic degradation of endogenous cardioprotective peptides, establishing modern heart failure guideline standards.

Biological Systems & Signaling Mechanisms

Cardiovascular peptides regulate smooth muscle relaxation, renal sodium filtration, and inotropic contractility.

Detailed biological signaling pathway schematic for Cardiovascular Peptides & Hemodynamic Regulation
Integrated biological signaling pathways and physiological mechanisms in Cardiovascular Peptides & Hemodynamic Regulation.

Natriuretic Receptor Particulate Guanylyl Cyclase (cGMP)

ANP and BNP bind NPR-A, stimulating intracellular cGMP synthesis, activating Protein Kinase G (PKG), and promoting smooth muscle relaxation.

Evidence Domain: Hemodynamic Signaling

Angiotensin AT1 Receptor Vasoconstriction

Angiotensin II binds Gq-coupled AT1 receptors, mobilizing IP3 and calcium to cause potent systemic vasoconstriction and aldosterone release.

Evidence Domain: Vascular Physiology

V1a Vascular Resistance Elevation

Vasopressin activates V1a receptors on vascular smooth muscle to restore systemic vascular resistance during vasoplegic shock.

Evidence Domain: Critical Care

Peptide Classes & Molecular Targets

Cardiovascular peptide therapeutics span natriuretic agonists, vasoconstrictors, and degradation inhibitors.

Natriuretic Peptide Agonists

Target: Nesiritide (rhBNP), Cenderitide
Historical Acute Heart Failure Therapy
Classification Endogenous / Synthetic
Clinical Standing Historical Acute Heart Failure Therapy
Physiological & Pharmacological Action:

Recombinant human natriuretic peptides engineered to reduce cardiac filling pressures.

Key Representative Agents: Nesiritide (rhBNP), Cenderitide

Synthetic Vasoconstrictor Peptides

Target: Angiotensin II (Giapreza), Vasopressin (Vasostrict)
FDA-Approved Critical Care Medicines
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved Critical Care Medicines
Physiological & Pharmacological Action:

Peptides indicated for refractory vasodilatory and septic shock.

Key Representative Agents: Angiotensin II (Giapreza), Vasopressin (Vasostrict)

Neprilysin-Protected Cardioprotective Systems

Target: Sacubitril (in Entresto ARNI combination)
Global Guideline-Directed Heart Failure Therapy
Classification Endogenous / Synthetic
Clinical Standing Global Guideline-Directed Heart Failure Therapy
Physiological & Pharmacological Action:

Inhibiting neutral endopeptidase (neprilysin) to extend endogenous ANP, BNP, and bradykinin half-lives.

Key Representative Agents: Sacubitril (in Entresto ARNI combination)

Human Clinical Trials & Observational Data

Pivotal randomized trials evaluate hemodynamic restoration in intensive care and heart failure survival.

Trial / Study Identifier / Compound Phase & Cohort Status / Duration Primary Findings
PARADIGM-HF Landmark Heart Failure Trial
PARADIGM-HF Landmark Heart Failure Trial
NCT01035255 		Phase 3 Double-Blind RCT
8442 heart failure patients with reduced ejection fraction
 Completed 20% reduction in cardiovascular death or heart failure hospitalization with neprilysin inhibition vs enalapril.
Published 2014
ATHOS-3: Phase 3 Study of LJPC-501 (Angiotensin II) in Catecholamine-Resistant Hypotension
ATHOS-3: Phase 3 Study of LJPC-501 (Angiotensin II) in Catecholamine-Resistant Hypotension
NCT02338843 		Phase 3 Double-Blind RCT
321 treated patients with catecholamine-resistant vasodilatory shock (344 randomized)
 Completed Mean arterial pressure response at hour 3 in 69.9% with angiotensin II vs 23.4% with placebo (P<0.001); 28-day mortality did not differ significantly.
Published 2017

Approved Medicines vs. Investigational Compounds

Clear distinction between regulatory-approved prescription medicines and experimental candidates undergoing laboratory or early clinical testing.

Compound Target / Mechanism Regulatory Status Indications / Focus Sponsor / Developer
Angiotensin II (Giapreza) Approved Biological Target FDA/EMA Approved (2017) Vasodilatory Septic Shock La Jolla Pharmaceutical / Innoviva
Vasopressin (Vasostrict) Approved Biological Target FDA/EMA Approved (2014) Vasodilatory Shock Refractory to Norepinephrine Par Sterile Products
Sacubitril / Valsartan (Entresto) Approved Biological Target FDA/EMA Approved (2015) Heart Failure with Reduced & Preserved EF Novartis
Cenderitide (CD-NP) Dual NPR-A / NPR-B designer natriuretic peptide Phase 2 Clinical Development Preclinical / Investigational Mayo Clinic / Biotech

Safety Realities & Hemodynamic Hazards

Vasoactive peptide interventions carry immediate risks of profound hypotension, severe ischemia, or fluid overload.

Excessive Peripheral Vasoconstriction

Severe / ICU Monitored

Potent vasoconstrictors (angiotensin II, vasopressin) can cause digital, mesenteric, or myocardial ischemia if infused excessively.

Angioedema Risk with Neprilysin Inhibition

Severe / Life-Threatening

Because neprilysin degrades bradykinin, combining neprilysin inhibitors with ACE inhibitors causes severe angioedema (mandating 36h washout).

Unresolved Scientific Questions

Key mechanistic and translational questions currently under active scientific investigation.

Can designer natriuretic peptides provide renal protection without inducing systemic hypotension?

Engineering peptides that selectively activate renal NPR-A receptors while sparing peripheral resistance vessels.

What are the long-term microvascular outcomes of GLP-1 cardiovascular protection?

Elucidating the exact endothelial versus autonomic mechanisms driving MACE reductions in the LEADER and SELECT landmark trials.

Evolution of Research & Milestones

Historical scientific breakthroughs, isolation events, structural discoveries, and regulatory milestones.

1981

Atrial Natriuretic Factor Discovered

de Bold and colleagues discover that atrial extract injections induce rapid natriuresis.

2014

PARADIGM-HF Published

Neprilysin peptide-protection establishes historic heart failure mortality benefit.

2017

Giapreza FDA Approval

Synthetic human angiotensin II approved for refractory vasodilatory shock.

Scientific References

Primary scientific publications, randomized controlled trials, and clinical consensus papers referenced in this field overview.

  1. Angiotensin-neprilysin inhibition versus enalapril in heart failure McMurray JJ et al. N Engl J Med 2014. N Engl J Med · 2014
    Source
  2. Angiotensin II for the treatment of vasodilatory shock Khanna A et al. N Engl J Med 2017. N Engl J Med · 2017
    Source
  3. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats de Bold AJ et al. Life Sci 1981. Life Sci · 1981
    Source

Scientific & Educational Disclaimer

InsidePeptides.org provides scientific and educational analysis of peer-reviewed research for informational purposes only. This overview does not constitute medical advice, diagnosis, treatment, prescription, or clinical guidance. Incretin and metabolic peptide medicines require physician oversight, prescription authorization, and regular clinical monitoring. Never adjust, initiate, or discontinue prescribed treatments without direct consultation with a qualified medical specialist.